SORAFENIB VIATRIS 200 mg, film-coated tablet 112 tablets
Active ingredients: Sorafenib, Sorafenib tosylate
Commercialized according to BDPMDispensing in France: Prescription only
Film-coated tablet112 tabletsorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- SORAFENIB VIATRIS 200 mg, comprimé pelliculé
- Pharmaceutical form
- comprimé pelliculé
- Route of administration
- orale
- Presentation description
- plaquette(s) aluminium PVC polyéthylène PVDC de 112 comprimé(s)
- Marketing authorisation holder
- VIATRIS SANTE
- Reimbursement according to BDPM
- 100 %
- Reimbursement conditions
- Ce médicament peut être pris en charge ou remboursé par l'Assurance Maladie dans les cas suivants :<br><br>- traitement du carcinome thyroïdien (cancer de la thyroïde)<br>- traitement du carcinome hépatocellulaire (cancer du foie) chez les patients de bon pronostic ayant une cirrhose hépatique. ; JOURNAL OFFICIEL ; 01/12/06
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 22 Jul 2021
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Requires special monitoring during treatment
- Prescribed by a hospital doctor
- Prescribed by specialists only
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
61442353CIP73021205CIP133400930212059Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| TOSILATE DE SORAFÉNIBcomprimé | 274,0 mg · un comprimé | SA |
| SORAFÉNIBcomprimé | 200 mg · un comprimé | FT |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.